Peer-reviewed veterinary case report
Prognostic factors for dogs with T-cell lymphoma treated with LOPP
By Blaxill, John et al.·Published in Veterinary and comparative oncology·2022·University of Sydney Veterinary Teaching Hospital, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with aggressive T-cell lymphoma were treated with a combination chemotherapy called LOPP, which includes lomustine, vincristine, procarbazine, and prednisolone. The study found that dogs receiving more treatments and those with hypercalcemia (high calcium levels) had better outcomes, with an average survival time of about 202 days. Some dogs responded well to treatment, with a complete response lasting an average of 316 days. This suggests that LOPP chemotherapy can be an effective first-line option for dogs with this type of lymphoma, especially if they have hypercalcemia.
People also search for: dog lymphoma treatment · T-cell lymphoma in dogs · chemotherapy for dogs with cancer
Abstract
Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL). Studies evaluating prognostic factors for dogs with TCL treated with LOPP chemotherapy are lacking. The aim of this retrospective study was to assess potential prognostic factors for canine naïve non-indolent TCL treated with the LOPP protocol. This was a retrospective cohort study of naïve non-indolent TCL treated with the LOPP chemotherapy protocol at a single specialty veterinary oncology clinic. Sixty-seven dogs met the inclusion criteria. The outcomes assessed included progression free survival (PFS), overall survival time (OST) and duration of complete response (DCR). The overall median PFS was 118 days (range 7-2302 days). The median OST was 202 days (range 8-2302 days). The overall median DCR was 316 days (range 38-2261 days). Number of treatments administered (p < .0001), multicentric disease (p = .044) and the presence of hypercalcaemia (p = .006) were prognostic indicators for PFS. Increasing number of treatments (p < .0001) and age (p = .0088) were prognostic indicators for OST. To our knowledge, this is the first study to describe hypercalcaemia as a positive prognostic indicator of PFS for TCL treated with LOPP chemotherapy. LOPP chemotherapy can be considered as a first-line treatment protocol against naïve hypercalcaemic non-indolent TCL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34464024/